The historical rank and industry rank for Ionis Pharmaceuticals's OCF Margin % or its related term are showing as below:
FRA:ISI'
s OCF Margin % Range Over the Past 10 Years
Min: -71.04 Med: -12.33 Max: 100.54
Current: -85.99
During the past 13 years, the highest OCF Margin % of Ionis Pharmaceuticals was 100.54%. The lowest was -71.04%. And the median was -12.33%.
FRA:ISI's OCF Margin % is ranked worse than 51.83% of 957
companies
in the Biotechnology industry
Industry Median: -66.52
vs FRA:ISI: -85.99
Ionis Pharmaceuticals OCF Margin % Related Terms
Ionis Pharmaceuticals OCF Margin % Historical Data
* Premium members only.
The historical data trend for Ionis Pharmaceuticals's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ISI vs EXEL, BBIO, AXSM: OCF Margin % Comparison
For the Biotechnology subindustry, Ionis Pharmaceuticals's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals (FRA:ISI) has a OCF Margin % of -322.16% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Ionis Pharmaceuticals and its competitors. According to the industry distribution chart, Ionis Pharmaceuticals ranks #496 out of 957 companies in the Biotechnology industry, placing it in the top 51.8%.
Is Ionis Pharmaceuticals' OCF Margin % too high?
Ionis Pharmaceuticals' current OCF Margin % is -322.16%. Based on the distribution chart, Ionis Pharmaceuticals ranks #496 out of 957 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ionis Pharmaceuticals has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' OCF Margin % compare to EXEL and BBIO?
According to the Biotechnology industry distribution chart, Ionis Pharmaceuticals ranks #496 out of 957 companies for OCF Margin %. This places Ionis Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current OCF Margin % is -322.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (FRA:ISI) is currently considered Significantly Overvalued. The stock's GF Value™ is €47.81, compared to a current price of €71.72 — trading 50% above its estimated fair value. The current OCF Margin % is -322.16%. Ionis Pharmaceuticals' overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Ionis Pharmaceuticals (FRA:ISI), the current OCF Margin % is -322.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (FRA:ISI) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of €71.72 is trading 50% above its estimated GF Value™ of €47.81.
GuruFocus considers Ionis Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:ISI:
OCF Margin %: -322.16%
GF Value™: €47.81 vs. price of €71.72 (50% above fair value)
No single metric tells the full story. See the FRA:ISI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
65GF Score
Get the complete analysis for FRA:ISI
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ISI has been successfully added to your 
